11/27
06:18 am
mck
McKesson (NYSE:MCK) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
McKesson (NYSE:MCK) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/26
02:12 pm
mck
McKesson (NYSE:MCK) had its "buy (a-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
McKesson (NYSE:MCK) had its "buy (a-)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
07:33 pm
mck
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints [Yahoo! Finance]
Low
Report
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints [Yahoo! Finance]
11/15
12:21 am
mck
McKesson Corporation (MCK) Strong Quarter Spurs Analyst Confidence [Yahoo! Finance]
Low
Report
McKesson Corporation (MCK) Strong Quarter Spurs Analyst Confidence [Yahoo! Finance]
11/14
01:15 pm
mck
McKesson (NYSE:MCK) had its "buy (b+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
McKesson (NYSE:MCK) had its "buy (b+)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
09:25 am
mck
McKesson (NYSE:MCK) had its price target raised by analysts at Wells Fargo & Company from $816.00 to $914.00. They now have an "equal weight" rating on the stock.
Low
Report
McKesson (NYSE:MCK) had its price target raised by analysts at Wells Fargo & Company from $816.00 to $914.00. They now have an "equal weight" rating on the stock.
11/10
08:18 am
mck
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar? [Yahoo! Finance]
Low
Report
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar? [Yahoo! Finance]
11/6
03:08 pm
mck
McKesson (NYSE:MCK) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
McKesson (NYSE:MCK) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
11/6
12:47 pm
mck
McKesson (NYSE:MCK) had its price target raised by analysts at Robert W. Baird from $873.00 to $927.00. They now have an "outperform" rating on the stock.
Low
Report
McKesson (NYSE:MCK) had its price target raised by analysts at Robert W. Baird from $873.00 to $927.00. They now have an "outperform" rating on the stock.
11/6
12:47 pm
mck
McKesson (NYSE:MCK) had its price target raised by analysts at UBS Group AG from $920.00 to $980.00. They now have a "buy" rating on the stock.
Low
Report
McKesson (NYSE:MCK) had its price target raised by analysts at UBS Group AG from $920.00 to $980.00. They now have a "buy" rating on the stock.
11/6
10:02 am
mck
McKesson (NYSE:MCK) had its price target raised by analysts at Morgan Stanley from $857.00 to $916.00. They now have an "overweight" rating on the stock.
Low
Report
McKesson (NYSE:MCK) had its price target raised by analysts at Morgan Stanley from $857.00 to $916.00. They now have an "overweight" rating on the stock.
11/5
04:10 pm
mck
McKesson Corporation Reports Fiscal 2026 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
Low
Report
McKesson Corporation Reports Fiscal 2026 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
10/31
08:08 pm
mck
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics [Yahoo! Finance]
Low
Report
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics [Yahoo! Finance]
10/30
08:00 am
mck
McKesson Corporation Declares Quarterly Dividend
Low
Report
McKesson Corporation Declares Quarterly Dividend
10/29
08:01 am
mck
McKesson (NYSE:MCK) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
McKesson (NYSE:MCK) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/27
09:03 am
mck
McKesson (NYSE:MCK) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
McKesson (NYSE:MCK) had its "buy" rating reaffirmed by analysts at UBS Group AG.
10/13
08:01 pm
mck
McKesson (NYSE:MCK) was given a new $900.00 price target on by analysts at Jefferies Financial Group Inc.. They now have a "buy" rating on the stock.
Low
Report
McKesson (NYSE:MCK) was given a new $900.00 price target on by analysts at Jefferies Financial Group Inc.. They now have a "buy" rating on the stock.
10/13
08:26 am
mck
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings [Yahoo! Finance]
Low
Report
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings [Yahoo! Finance]
10/11
04:06 am
mck
McKesson Corporation Transforming Towards High-Margin Operations: Why I Choose To Buy [Seeking Alpha]
Low
Report
McKesson Corporation Transforming Towards High-Margin Operations: Why I Choose To Buy [Seeking Alpha]
10/11
02:12 am
mck
McKesson: Strategic Shift To High-Growth Oncology And Prescription Tech Signals Long Opportunity [Seeking Alpha]
Low
Report
McKesson: Strategic Shift To High-Growth Oncology And Prescription Tech Signals Long Opportunity [Seeking Alpha]
10/8
10:29 pm
mck
How Analysts See McKesson's Story Changing After New Targets and Upbeat Investor Day [Yahoo! Finance]
Low
Report
How Analysts See McKesson's Story Changing After New Targets and Upbeat Investor Day [Yahoo! Finance]
10/8
02:22 pm
mck
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio [Yahoo! Finance]
Neutral
Report
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio [Yahoo! Finance]
10/6
10:26 am
mck
Oath Surgical Raises $24M to Build the First Surgeon-Owned, AI-Powered Surgical System [Yahoo! Finance]
Low
Report
Oath Surgical Raises $24M to Build the First Surgeon-Owned, AI-Powered Surgical System [Yahoo! Finance]
10/6
08:08 am
mck
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) [Yahoo! Finance]
Low
Report
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) [Yahoo! Finance]
10/6
07:23 am
mck
Cell and Gene Therapies on the Rise: New Report Reveals Growing Adoption and Persistent Challenges [Yahoo! Finance]
Low
Report
Cell and Gene Therapies on the Rise: New Report Reveals Growing Adoption and Persistent Challenges [Yahoo! Finance]